MEDICINOVA, INC. Operating Lease, Right-of-Use Asset, Amortization Expense
MEDICINOVA, INC. (MNOV) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $45.18 thousand for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-12.
Discontinued › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2022-05-12
- MEDICINOVA, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2022-03-31 was $45.18K, a 19.04% decline year-over-year.
- MEDICINOVA, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2021-03-31 was $55.81K.
- MEDICINOVA, INC. operating lease, right-of-use asset, amortization expense for fiscal 2021 was $216.64K, a 3.06% increase from fiscal 2020.
- MEDICINOVA, INC. operating lease, right-of-use asset, amortization expense for fiscal 2020 was $210.21K.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|
| 2022-03-31 | $45.18K 10-Q · filed 2022-05-12 | |
| 2021-12-31 | $216.64K 10-K · filed 2022-02-16 | |
| 2021-03-31 | $55.81K 10-Q · filed 2022-05-12 | |
| 2020-12-31 | $210.21K 10-K · filed 2022-02-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |